患者招募:卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究

2020-12-23 NMPA NMPA

一、题目和背景信息

一、题目和背景信息
登记号 CTR20202571
相关登记号  
药物名称 注射用卡瑞利珠单抗   曾用名:
药物类型 生物制品
临床申请受理号 企业选择不公示
适应症 非小细胞肺癌
试验专业题目 卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究
试验通俗题目 卡瑞利珠单抗联合法米替尼治疗非小细胞肺癌研究
试验方案编号 SHR-1210-III-324 方案最新版本号 1.0
版本日期: 2020-08-13 方案是否为联合用药
二、申请人信息
申请人名称
1
2
3
联系人姓名 于素强 联系人座机 0518-82342973 联系人手机号 15508608847
联系人Email yusuqiang@hrglobe.cn 联系人邮政地址 上海市-上海市-浦东新区海科路1288号15层 联系人邮编 201210
三、临床试验信息
1、试验目的

评估卡瑞利珠单抗联合苹果酸法米替尼胶囊与培美曲塞和卡铂对比卡瑞利珠单抗联合安慰剂与培美曲塞和卡铂一线治疗晚期或转移性非鳞状非小细胞肺癌的无进展生存期(progression free survival,PFS)

2、试验设计
试验分类 安全性和有效性 试验分期 III期 设计类型 平行分组
随机化 随机化 盲法 双盲 试验范围 国内试验
3、受试者信息
年龄 18岁(最小年龄)至 70岁(最大年龄)
性别 男+女
健康受试者
入选标准
1 受试者签署知情同意书时年龄18-70周岁,男女均可;
2 组织学或细胞学确诊为非鳞状非小细胞肺癌(NSCLC)、并且为 IIIB 期-IV期肿瘤;
3 研究中心必须能够提供受试者EGFR突变和ALK易位状况的相关文件资料,且必须均为阴性;
4 必须提供诊断为晚期或转移性肿瘤时或之后的肿瘤组织标本(仅适用于第二阶段研究);
5 受试者既往未接受过针对晚期/转移性NSCLC的全身系统性化疗;
6 按照RECIST 1.1标准,受试者必须有通过CT或MRI检查的可测量靶病灶;
7 ECOG PS评分:0-1分;
8 预期的生存期≥3个月;
9 有充足的器官和骨髓功能;
10 育龄期女性受试者必须在首次用药前7天内进行血清妊娠试验,且结果为阴性,并且愿意在研究期间和末次给予研究药物后3个月内采用一种经医学认可的高效避孕措施(如:宫内节育器、避孕药或避孕套);对于伴侣为育龄期女性的男性受试者,需手术绝育,或同意在研究期间和末次研究给药后3个月内采用有效的方法避孕;
11 经本人同意并已签署知情同意书,愿意并有能力遵从计划的访视、研究治疗、实验室检查及其他试验程序。
排除标准
1 其他病理组织学类型的非小细胞肺癌受试者;
2 癌性脑膜炎、脊髓压迫等;
3 未经治疗的中枢神经系统(CNS)肿瘤转移;
4 可以手术切除或根治性放射治疗的受试者;
5 曾接受过抗PD-1(L1)或CTLA4单抗、VEGF或VEGFR信号通路单靶点/多靶点抑制剂或单抗治疗的受试者;
6 存在任何活动性、已知或可疑自身免疫疾病;
7 首次用药前14天内,需要使用皮质类固醇(>10 mg/天的泼尼松或等价物)或其他免疫抑制剂进行系统治疗;
8 首次用药前1个月内用过抗肿瘤疫苗或其他具有免疫刺激作用的抗肿瘤药;
9 首次用药前14天内使用过抗肿瘤中药;
10 正在参加其他临床研究或首次用药时间距离前一项临床研究结束(末次给药)时间少于4周或该研究药物的5个半衰期,以较短者为准;
11 预期在研究中需要任何其它形式的抗肿瘤治疗;
12 首次用药前4周内接受重大外科手术者,首次用药前4周内>30 Gy的非胸部放射治疗者,首次用药前24周内>30 Gy的胸部放射者,以及首次用药前2周内接受≤30 Gy的姑息性放射者,且未能从这些干预措施的毒性和/或并发症恢复至NCI-CTC AE ≤1度(脱发和疲劳除外)的受试者;
13 高度怀疑有间质性肺炎的受试者;或可能会干扰可疑的药物相关肺毒性的检测或处理的受试者;或其他严重影响肺功能的中重度肺部疾病;
14 有恶性肿瘤病史的受试者;
15 患有严重的心脑血管疾病的受试者;
16 患有高血压,且经降压药物治疗无法获得良好控制者;
17 首次用药前3个月内出现过显著临床意义的出血症状或具有明确的出血倾向,如消化道出血、出血性胃溃疡。受试者在首次用药前的1个月内存在明显的咳血、每次咯血量达半茶勺(2.5 mL)或以上不能入组;
18 首次用药前6个月内发生动/静脉血栓事件,如脑血管意外(包括暂时性缺血性发作、脑出血、脑梗塞)、深静脉血栓及肺栓塞等;
19 需要使用华法林或肝素长期抗凝治疗的受试者;
20 需要长期抗血小板治疗;
21 肿瘤已侵犯重要血管或经研究者判断患者肿瘤在治疗期间有极高可能侵袭重要血管而引起大出血的情况;
22 伴有活动性肺结核(TB)的受试者;
23 首次用药前4周内发生过严重感染的受试者,包括但不局限于需要住院治疗的感染并发症,菌血症,重症肺炎等。排除首次用药前2周内存在需系统抗生素治疗的CTCAE≥2级的活动性感染的受试者;
24 准备进行或者既往接受过组织/器官移植的受试者;
25 研究者认为可能影响口服药物吞咽、消化、吸收的胃肠道疾病或手术史;
26 首次用药前30天内接种过或将接种活疫苗的受试者;
27 不建议入选伴有未控制的肿瘤相关疼痛的受试者;
28 已知有人类免疫缺陷病毒(HIV)检查阳性病史或已知有获得性免疫缺陷综合征(艾滋病);
29 活动性乙肝或丙肝患者;
30 伴有未控制的需要反复(一月一次或更加频繁)引流的胸腔积液、心包积液,或腹水的受试者;
31 对其他单克隆抗体发生过重度过敏反应;
32 对输液发生过过敏或不耐受;
33 对培美曲塞、卡铂或其预防用药等有严重过敏史;
34 伴有精神疾病、酗酒、无法戒烟、吸毒或药物滥用等情况的受试者;
35 根据研究者的判断,排除患有可能混淆研究结果、干扰受试者参与研究程序或不符合受试者参加研究最佳利益的任何疾病、治疗或实验室异常的病史或当前证据的受试者。
4、试验分组
试验药
序号 名称 用法
1 中文通用名:注射用卡瑞利珠单抗
英文通用名:Camrelizumab for Injection
商品名称:艾瑞卡
剂型:注射剂
规格:200 mg/支
用法用量:静脉滴注
用药时程:按方案使用
2 中文通用名:苹果酸法米替尼胶囊
英文通用名:Famitinib malate capsule
商品名称:NA
剂型:胶囊剂
规格:15mg/粒
用法用量:口服
用药时程:按方案使用
3 中文通用名:注射用培美曲塞二钠
英文通用名:Pemetrexed Disodium for Injection
商品名称:普来乐
剂型:注射剂
规格:500mg/㎡
用法用量:静脉滴注
用药时程:按方案使用
4 中文通用名:注射用卡铂
英文通用名:Carboplatin fou Injection
商品名称:波贝
剂型:注射剂
规格:0.1g/支
用法用量:静脉滴注
用药时程:按方案使用
对照药
序号 名称 用法
1 中文通用名:注射用卡瑞利珠单抗
英文通用名:Camrelizumab for Injection
商品名称:艾瑞卡
剂型:注射剂
规格:200 mg/支
用法用量:静脉滴注
用药时程:按方案使用
2 中文通用名:苹果酸法米替尼胶囊安慰剂
英文通用名:Falmitinib malate capsule placebo
商品名称:NA
剂型:胶囊剂
规格:15mg/粒
用法用量:口服
用药时程:按方案使用
3 中文通用名:注射用培美曲塞二钠
英文通用名:Pemetrexed Disodium for Injection
商品名称:普来乐
剂型:注射剂
规格:500mg/㎡
用法用量:静脉滴注
用药时程:按方案使用
4 中文通用名:注射用卡铂
英文通用名:Carboplatin fou Injection
商品名称:波贝
剂型:注射剂
规格:0.1g/支
用法用量:静脉滴注
用药时程:按方案使用
5、终点指标
主要终点指标及评价时间
序号 指标 评价时间 终点指标选择
1 指标:药代动力学:卡瑞利珠单抗的血清浓度以及法米替尼的血浆浓度和药动学参数(AUC0-t、AUC0-∞(如适用)、Cmax、Tmax、t1/2z 、Vz/F、CL/F); 首次用药至末次访视 安全性指标
2 指标:不良事件(AE)及严重不良事件(SAE)的发生率及严重程度 首次用药至末次访视 安全性指标
3 指标:无进展生存期(PFS) 首次用药至末次访视 有效性指标
次要终点指标及评价时间
序号 指标 评价时间 终点指标选择
1 指标;客观缓解率(ORR) 首次用药至末次访视 有效性指标
2 指标:缓解持续时间(DoR) 首次用药至末次访视 有效性指标
3 指标:无进展生存期(PFS) 首次用药至末次访视 有效性指标
4 指标:总生存期(OS) 首次用药至末次访视 有效性指标
5 指标:客观缓解率(ORR) 首次用药至末次访视 有效性指标
6 指标:缓解持续时间(DoR) 首次用药至末次访视 有效性指标
7 指标:疾病控制率(DCR) 首次用药至末次访视 有效性指标
8 指标:不良事件(AE)及严重不良事件(SAE)的发生率及严重程度 首次用药至末次访视 安全性指标
9 指标:相对于基线,研究期间形成的抗卡瑞利珠单抗抗体(ADA)以及中和抗体(Nab)比例 首次用药至末次访视 安全性指标
10 指标:生物标志物:肿瘤组织标本中PD-L1表达量 首次用药至末次访视 有效性指标
6、数据安全监查委员会(DMC)

7、为受试者购买试验伤害保险

四、研究者信息
1、主要研究者信息
1 姓名 周彩存 学位 医学博士 职称 主任医师
电话 021-65115006 Email caicunzhoudr@163.com 邮政地址 上海市-上海市-政民路507号
邮编 200433 单位名称 上海市肺科医院
2、各参加机构信息
序号 机构名称 主要研究者 国家 省(州) 城市
1 上海市肺科医院 周彩存 中国 上海市 上海市
2 上海上海交通大学医学院附属瑞金医院 项轶 中国 上海市 上海市
3 上海市杨浦区中心医院 郑翠侠 中国 上海市 上海市
4 上海中医药大学附属龙华医院 李和根 中国 上海市 上海市
5 浙江省肿瘤医院 范云 中国 浙江省 杭州市
6 浙江大学附属第二医院 李雯 中国 浙江省 杭州市
7 浙江大学邵逸夫医院 方勇 中国 浙江省 杭州市
8 浙江省台州医院 吕冬青 中国 浙江省 台州市
9 东南大学附属中大医院 章锐锋 中国 江苏省 南京市
10 淮安市第一人民医院 孟自力 中国 江苏省 淮安市
11 苏北人民医院 徐兴祥 中国 江苏省 扬州市
12 安徽医科大学第一附属医院 顾康生 中国 安徽省 合肥市
13 安徽医科大学第二附属医院 赵卉 中国 安徽省 合肥市
14 安徽省立医院 潘跃银 中国 安徽省 合肥市
15 北京协和医院 张力 中国 北京市 北京市
16 北京大学肿瘤医院胸内一科 赵军 中国 北京市 北京市
17 北京大学肿瘤医院胸内二科 方健 中国 北京市 北京市
18 中国医学科学院肿瘤医院 胡兴胜 中国 北京市 北京市
19 首都医科大学附属北京胸科医院 李宝兰 中国 北京市 北京市
20 中国人民解放军总医院 马俊勋 中国 北京市 北京市
21 天津市肿瘤医院 任秀宝 中国 天津市 天津市
22 哈尔滨医科大学附属肿瘤医院 刘宝刚 中国 黑龙江省 哈尔滨市
23 吉林省肿瘤医院 程颖 中国 吉林省 长春市
24 中国医科大学附属第一医院 刘云鹏 中国 辽宁省 沈阳市
25 中国医科大学附属盛京医院 吴荣 中国 辽宁省 沈阳市
26 大连医科大学附属第二医院 戴朝霞 中国 辽宁省 大连市
27 内蒙古医科大学附属医院 高俊珍 中国 内蒙古自治区 呼和浩特市
28 赤峰市医院 季洪波 中国 内蒙古自治区 赤峰市
29 河北医科大学第四医院 丁翠敏 中国 河北省 石家庄市
30 邢台市人民医院 郭军 中国 河北省 邢台市
31 山西省肿瘤医院 杨卫华 中国 山西省 太原市
32 山西白求恩医院 刘先胜 中国 山西省 太原市
33 长治市人民医院 赵宪平 中国 山西省 长治市
34 山东省肿瘤医院 刘志芳 中国 山东省 济南市
35 济南市中心医院 孙玉萍 中国 山东省 济南市
36 青岛市中心医院 马学真 中国 山东省 青岛市
37 河南省肿瘤医院 赵艳秋 中国 河南省 郑州市
38 郑州市中心医院 易善永 中国 河南省 郑州市
39 河南科技大学第一附属医院 孙江涛 中国 河南省 洛阳市
40 西安交通大学医学院第一附属医院 李满祥 中国 陕西省 西安市
41 西安交通大学医学院第二附属医院 杨栓盈 中国 陕西省 西安市
42 新疆医科大学附属肿瘤医院 刘春玲 中国 新疆维吾尔自治区 乌鲁木齐市
43 四川省肿瘤医院 周进 中国 四川省 成都市
44 四川大学华西医院 王永生 中国 四川省 成都市
45 川北医学院附属医院 马代远 中国 四川省 南充市
46 陆军特色医学中心 李梦侠 中国 重庆市 重庆市
47 重庆医科大学附属第一医院 郭述良 中国 重庆市 重庆市
48 遵义医科大学大学附属医院 周亮 中国 贵州省 遵义市
49 云南省肿瘤医院 黄云超 中国 云南省 昆明市
50 华中科技大学同济医学院附属协和医院 伍钢 中国 湖北省 武汉市
51 湖北省肿瘤医院 胡胜 中国 湖北省 武汉市
52 湖北十堰市人民医院 曹风军 中国 湖北省 十堰市
53 湖南省肿瘤医院 陈建华 中国 湖南省 长沙市
54 中南大学湘雅医院 潘频华 中国 湖南省 长沙市
55 南昌大学第一附属医院 左玮 中国 江西省 南昌市
56 南昌大学第二附属医院 刘安文 中国 江西省 南昌市
57 福建医科大学附属协和医院 林小燕 中国 福建省 福州市
58 厦门大学附属第一医院 史永红 中国 福建省 厦门市
59 广州医科大学附属第一医院 周承志 中国 广东省 广州市
60 南方医科大学南方医院 廖旺军 中国 广东省 广州市
61 南方医科大学珠江医院 张健 中国 广东省 广州市
62 广东医科大学附属医院 杨志雄 中国 广东省 湛江市
63 广西医科大学附属肿瘤医院 于起涛 中国 广西壮族自治区 南宁市
64 柳州市工人医院 黄东宁 中国 广西壮族自治区 柳州市
65 海南省人民医院 陈永倖 中国 海南省 海口市
66 宁夏医科大学总院 王蕊 中国 宁夏回族自治区 银川市
67 广西医科大学第一附属医院 覃寿明 中国 广西壮族自治区 南宁市
68 新乡医学院第一附属医院 姬颖华 中国 河南省 新乡市
五、伦理委员会信息
序号 名称 审查结论 批准日期/备案日期
1 上海市肺科医院医学伦理委员会 同意 2020-10-30

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2021-02-13 ms3000000728156085

    点赞一个!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2021-03-25 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]
    2020-12-25 xlxchina
  10. [GetPortalCommentsPageByObjectIdResponse(id=2059949, encodeId=c90d205994900, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon May 31 22:36:43 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924412, encodeId=440592441257, content=点赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ac5447033, createdName=ms3000000728156085, createdTime=Sat Feb 13 10:22:11 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775542, encodeId=73b21e75542b1, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 25 05:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990743, encodeId=3a9b1990e4364, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Dec 26 03:36:43 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904045, encodeId=dafe1904045a8, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Jan 28 06:36:43 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502866, encodeId=6d501502866ee, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573103, encodeId=8a0215e31036e, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600888, encodeId=d358160088863, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Dec 25 04:36:43 CST 2020, time=2020-12-25, status=1, ipAttribution=)]

相关资讯

Cell Death Dis:SKIL促进非小细胞肺癌的发生和免疫逃逸

非小细胞肺癌(NSCLC)目前仍是全球的主要健康威胁之一。尽管目前对于NSCLC有几种有效的治疗方法(如手术、放疗、化疗和靶向治疗),但NSCLC患者的预后仍不尽人意。在过去的几年里,免疫疗法已成为一

Lancet oncol:生物标志物指导非小细胞肺癌治疗的效果

肺癌主方案(Lung-MAP;S1400)是一个完整的生物标志物驱动的主方案,旨在解决鳞状非小细胞肺癌更好治疗的尚未满足的需求。创建Lung-MAP (S1400)旨在为生物标志物筛选和靶向治疗的快速

NEJM:奥西替尼作为非小细胞肺癌手术治疗后辅助治疗的疗效研究

对于IB至IIIA期EGFR突变阳性的非小细胞肺癌患者,在手术治疗后接受奥西替尼治疗可显著延长患者的无病生存期

JCO:BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用

约有3%-4%的晚期非小细胞肺癌(NSCLC)患者会发生脑膜上转移(LMs),在表皮生长因子受体突变(EGFRm)的NSCLC中,LM的发生率上升会上升到约9%。Osimertinib是第三代、不可逆

Cell Death Differ:KPNB1介导的PD-L1核转运激活Gas6/MerTK信号通路促进非小细胞肺癌细胞增殖

作为B7蛋白家族的重要成员,PD-L1(程序性细胞死亡配体1)能够通过与免疫细胞中表达的PD-1结合而促进肿瘤细胞的免疫逃逸。除了免疫抑制特性外,既往研究显示,PD-L1也被认为是促进肿瘤发生发展的关